Roche AG

Grenzacherstrasse 124, 4070 Basel
Roche AG   link
Location: Basel
Discipline: Pharmacology
Pharmacology - Health - Jan 27
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Pharmacology - Health - Jan 21

Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or refractory diffuse large B-cell lymphoma Polivy approval is based on a phase Ib/II study, the firs

Pharmacology - Health - Dec 13, 2019

Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).

Pharmacology - Health - Dec 11, 2019

Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurrence or death, corresponding to an absolute iDFS benefit of 4.5% at six years With longer f

Pharmacology - Health - Dec 8, 2019

In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia At four-year follow-up of the MURANO study, Venclexta/Venclyxto plus MabThera/Rituxan continued t

Pharmacology - Health - Dec 16, 2019

All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.

Pharmacology - Health - Dec 12, 2019

Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study showed non-inferior pharmacokinetics and comparable efficacy and safety with the fixed-dose combina

Health - Pharmacology - Dec 10, 2019

Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter. It is designed to help non-insulin-dependent people with type 2 diabetes or pre-diabetes live healthier lives in-between doctors' visits.

Pharmacology - Health - Dec 4, 2019

Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combinat





Website Preview

Link

Medicine and Life Sciences